Vascular Endothelial Growth Factor Sustained Delivery Augmented Cell Therapy Outcomes of Cardiac Progenitor Cells for Myocardial Infarction Publisher Pubmed



Montazeri L¹ ; Sobat M² ; Kowsariesfahan R¹ ; Rabbani S³ ; Ansari H⁴ ; Barekat M⁴ ; Firoozi S⁴ ; Rajabi S¹ ; Vahdat S⁴ ; Baharvand H^{4, 5} ; Pahlavan S⁴ Show Affiliations
Source: Journal of Tissue Engineering and Regenerative Medicine Published:2020

Abstract

Cell therapy has become a novel promising approach for improvement of cardiac functional capacity in the instances of ventricular remodeling and fibrosis caused by episodes of coronary artery occlusion and hypoxia. The challenge toward enhancing cell engraftment as well as formation of functional tissue, however, necessitated combinatorial approaches. Here, we complemented human embryonic stem cell-derived cardiac progenitor cell (hESC-CPC) therapy by heparin-conjugated, vascular endothelial growth factor (VEGF)-loaded fibrin hydrogel as VEGF delivery system. Transplantation of these cardiac committed cells along with sustained VEGF release could surpass the cardiac repair effects of each constituent alone in a rat model of acute myocardial infarction. The histological sections of rat hearts revealed improved vascularization as well as inclusion of hESC-CPC-derived cardiomyocytes, endothelial, and smooth muscle cells in host myocardium. Thus, co-transplantation of hESC-CPC and proangiogenic factor by a suitable delivery rate may resolve the shortcomings of conventional cell therapy. © 2020 John Wiley & Sons, Ltd.